Uterine Fibroid Treatment Market Size Worth $10.83 Billion By 2032 | CAGR: 9.30%

Uterine Fibroid Treatment Market Size Worth $10.83 Billion By 2032 | CAGR: 9.30%

The global uterine fibroid treatment market size is expected to reach USD 10.83 billion by 2032, according to a new study by Polaris Market Research. The report “Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Uterine fibroids (UF) are a common condition affecting women of reproductive age, with heavy menstrual bleeding being one of the most common symptoms. The development of novel drugs, such as GnRH antagonists and progestin-releasing IUDs, has provided more effective treatment options for women with uterine fibroids. These factors, along with increased awareness and diagnosis, are driving the growth of the market.

As per the analysis done by the IntechOpen, excessive menstrual bleeding is the most common symptom in the UF, affecting almost 1.4 Mn women each year. Moreover, around 60 percent of the women have reported the symptoms of physical in-activity and quality of life.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/uterine-fibroid-treatment-market/request-for-sample

Demand for more effective and safer treatment options for uterine fibroids is increasing, and this is driving research and development efforts in the field. With increased funding for research activities, the development of more advanced and innovative treatment options is expected, which will further drive the growth of the market. Additionally, the development of personalized medicine and precision therapies is also expected to drive growth in the market, as these approaches may offer more targeted and effective treatment options for individual patients.

The recent endorsement and reintroduction of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 by the Society for Women's Health Research (SWHR) will provide funding and support for research on uterine fibroids, which is expected to boost the development of novel treatments. Additionally, the recent approval of multiple GnRH antagonists such as Myfembree for the treatment of heavy bleeding associated with fibroids will also drive the market growth.

Uterine Fibroids Treatment Market Report Highlights

  • GnRH antagonists’ segment is anticipated to witness faster growth owing to its high efficacy and effective treatment option.
  • Sub-mucosal fibroids segment accounted for the larger market share. This is primarily due its high prevalence rate and severity. It is most common among Asian women
  • Retail pharmacies segment expected to garner substantial share, owing to easy availability of drugs and other combination therapies
  • North America is expected to grow larger revenue, owing to high prevalence rate in the US. presence of better medical facilities, and awareness among individuals about ill effects.
  • The global players include Myovant Sciences, Pfizer, Abbvie, Ferring, AstraZeneca, Bayer, Amring Pharmaceuticals, and Watson Pharma.

Polaris Market Research has segmented the uterine fibroids treatment market report based on drug type, drug class, end use, and region:

Uterine Fibroids Treatment, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroids Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Gonadotropin-releasing Hormone (GnRH) Agonists
  • Gonadotropin-releasing Hormone (GnRH) Antagonists
  • Progestin-releasing Intrauterine Device (IUD) & Contraceptives
  • Non-hormonal Medications
  • Others

Uterine Fibroids Treatment, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroids Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
    • U.S.
    • Canada
    • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Uterine Fibroid Treatment Market Report Scope

Report Attributes


Market size value in 2024

USD 5.32 billion

Revenue forecast in 2032

USD 10.83 billion


9.30% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments covered

By Drug Type, Drug Class, By End Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Myovant Sciences, Pfizer, Abbvie, Ferring, AstraZeneca, Bayer, Amring Pharmaceuticals, and Watson Pharma

For Specific Research Requirements

Request for Customized Report